OC1332367

OC1332367

University of British Columbia

Elite Note Taker
1228Uploads
2Likes
0Blog Articles
All Activity
Uploads (1228)
Blog Articles (0)
Homework Help (0)
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 28: Multiple Sclerosis, Grey Matter, Neurodegeneration

OC13323673 Page
7 Sep 2020
0
Educate on existing and new ms drugs on the horizon. Identify adverse drug reactions, drug interactions, and contraindications of ms medications with c
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 28: Glatiramer Acetate, Elevated Transaminases, Interferon Type I

OC13323674 Page
7 Sep 2020
0
Shown to reduce rate of relapses may ultimately delay/reduce disease progression. Only benefit rrms, not ppms or spms (little inflammation) Clinical tr
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 27: Acetylcholinesterase Inhibitor, Memantine, Nmda Receptor Antagonist

OC13323673 Page
7 Sep 2020
0
Blocks nmda receptor, preventing increased binding of glutamate and subsequent. Ca2+ influx prevent excitotoxicity and neuronal death. Monotherapy is r
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 28: Multiple Sclerosis, Optic Neuritis, Ocrelizumab

OC13323673 Page
7 Sep 2020
0
As disease progresses, patients will cycle between recovery and active states. First cns inflammatory demyelinating clinical episode of neurological sy
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 29: NEUR Ischemic Stroke and Acute Intracerebral Hemorrhage (Part 2)

OC13323674 Page
7 Sep 2020
0
Ischemic stroke and acute intracerebral hemorrhage (part 2) A brief episode of neurological dysfunction caused by focal brain, spinal cord or retinal i
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 29: NEUR Ischemic Stroke and Acute Intracerebral Hemorrhage (Part 1)

OC13323674 Page
7 Sep 2020
0
Describe the clinical presentation of an acute stroke or tia (transient ischemic attack). Distinguish between ischemic stroke and intracerebral hemorrh
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 27: NEUR Therapeutics of Dementia (Part 2)

OC13323673 Page
7 Sep 2020
0
Full physical and mental status examination to help identify the cause. Assess for reversible medical illnesses (e. g. vitamin b12 deficiency, hypothyr
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 29: NEUR Ischemic Stroke and Acute Intracerebral Hemorrhage (Part 4)

OC13323673 Page
7 Sep 2020
0
Ischemic stroke and acute intracerebral hemorrhage (part 4) Less processed foods, added or free sugars, saturated/trans fats, cholesterol. More natural
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 25: NEUR Pathophysiology & Pharmacology of Dementia (Part 2)

OC13323673 Page
7 Sep 2020
0
Pathophysiology & pharmacology of dementia (part 2) A substance, measurement or indicator of a biological state. Should detect a fundamental feature of
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 27: NEUR Therapeutics of Dementia (Part 1)

OC13323674 Page
7 Sep 2020
0
Dementia an umbrella term that covers many physical causes of cognitive decline. Frontotemporal lobar degeneration (relates to atrophy of certain parts
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 25: NEUR Pathophysiology & Pharmacology of Dementia (Part 1)

OC13323673 Page
7 Sep 2020
0
Pathophysiology & pharmacology of dementia (part 1) Dementia : a major neurocognitive disorder, in which a deficit in cognitive functioning characteriz
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 27: NEUR Therapeutics of Dementia (Part 3)

OC13323673 Page
7 Sep 2020
0
Recall moa related to cholinergic hypothesis : block w/ cholinesterase inhibitors, ach. 3 agents seem to be equal in efficacy. Initial choice is usuall
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 29: NEUR Ischemic Stroke and Acute Intracerebral Hemorrhage (Part 3)

OC13323673 Page
7 Sep 2020
0
Ischemic stroke and acute intracerebral hemorrhage (part 3) Aspirin is the standard antithrombotic therapy for most stroke patients. Starting aspirin a
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 25: NEUR Pathophysiology & Pharmacology of Dementia (Part 3)

OC13323673 Page
7 Sep 2020
0
Pathophysiology & pharmacology of dementia (part 3) Has to be in the right place, at the right time, and in the right amount. Too much or too little gl
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 24: Substantia Nigra, Urinary Incontinence, Neurodegeneration

OC13323673 Page
26 Apr 2020
0
Basal ganglia group of structures that is specifically related to movement. Substantia nigra where we see death of da neurons (50%) Dopamine helps to t
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 24: Gastroparesis, Comt Inhibitor, Dopamine Agonist

OC13323675 Page
26 Apr 2020
0
Up to 50% of patients after 5 years of l-dopa therapy will develop: motor fluctuations wearing off , on-off , freezing of gait , dyskinesias peak-dose
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 24: Comt Inhibitor, Entacapone, Nmda Receptor Antagonist

OC13323672 Page
26 Apr 2020
0
Tolcapone was first comt inhibitor approved in canada. Only available through hc"s special access programme for exceptional cases. Not used for early/i
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 23: Dopamine Receptor D2, Dopamine Receptor D3, Pramipexole

OC13323673 Page
26 Apr 2020
0
Pharmacology of parkinson"s disease medications (part 2) Found by accident to improve symptoms of pd. Antiviral drug used to reduce risk of influenza a
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 24: Special Access Program, Cardiac Fibrosis, Impulse Control Disorder

OC13323674 Page
26 Apr 2020
0
Moderately effective for motor symptoms (second to l-dopa) Lower risk of dyskinesias and motor complications. Need to titrate dose slowly (4-6 weeks) w
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 24: Progressive Supranuclear Palsy, Balance Disorder, Essential Tremor

OC13323674 Page
26 Apr 2020
0
More complications over time as we progress from early to advanced. Early postural instability, autonomic dysfunction, early and prominent dementia, im
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 20: NEUR Therapeutics of Migraine Medications (Part 3)

OC13323674 Page
26 Apr 2020
0
Treatment of severe, refractory migraine pain (i. e. status migrainosus) Treatment of severe nausea, vomiting, and subsequent dehydration. Detoxificati
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 23: NEUR Pharmacology of Parkinson’s Disease Medications (Part 1)

OC13323673 Page
26 Apr 2020
0
Pharmacology of parkinson"s disease medications (part 1) Slow disease progression no agent proven to do this. Preservation of function and ability to p
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 20: NEUR Therapeutics of Migraine Medications (Part 4)

OC13323674 Page
26 Apr 2020
0
Asa 1000 mg weak evidence that > placebo. Other: acupuncture, heat, ice, manual therapies, rest, biofeedback. Not recommended: butalbital and codeine p
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 17: NEUR Pharmacology of Headaches (Part 2)

OC13323672 Page
26 Apr 2020
0
Lasmitidan (ly573144) acts selectively at 5ht1f receptor. Recommended when the patient experiences 3 migraine attacks/month . 3 fundamental obstacles f
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 20: NEUR Therapeutics of Migraine Medications (Part 1)

OC13323674 Page
26 Apr 2020
0
Onset in middle age or older (> 40 years) Neurologic signs : stiff neck, focal signs, reduced consciousness. Nocturnal occurrence or on awakening in th
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 20: NEUR Therapeutics of Migraine Medications (Part 2)

OC13323673 Page
26 Apr 2020
0
Ergots (2nd/3rd line therapy that has fallen out of favor) Agonist at 5-ht1d receptors on intracranial blood vessels = vasoconstriction. Agonist at 5-h
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 19: NEUR Med Chem of Serotonin Receptor Agonists

OC13323675 Page
26 Apr 2020
0
Now appears to be a ubiquitous neurotransmitter involved in everything. Serotonin was initially thought to do nothing when initially discovered. Struct
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 22: NEUR Pathophysiology of Parkinson’s Disease (Part 1)

OC13323674 Page
26 Apr 2020
0
Loss of eye blink & facial tone (mask-like face) Dementia with lewy bodies (dlb) is a distinct form of dementia that appears early and has associated f
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 22: NEUR Pathophysiology of Parkinson’s Disease (Part 2)

OC13323673 Page
26 Apr 2020
0
Neurofilament proteins and ubiquitin are other important constituents of lbs. Loss of pigmentation in the substantia nigra (pars compacta) Lewy bodies
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 17: NEUR Pharmacology of Headaches (Part 1)

OC13323673 Page
26 Apr 2020
0
Abortive therapy may be effective for some patients. Moa: selective agonist for 5-ht1d and 5-ht-1b receptors. Binds with high affinity and selectivity
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 16: NEUR Pathophysiology of Headaches (Part 1)

OC13323672 Page
25 Apr 2020
0
Sensation of tightness or pressure across forehead or on the sides or back of head. People with tension headaches can also have migraines. Increased se
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 16: NEUR Pathophysiology of Headaches (Part 2)

OC13323673 Page
25 Apr 2020
0
Headache pain is felt when electrical stimuli were applied to the dura ( red circles ) adjacent to the main artery of the suprasagittal ( midline ) sin
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 15: Release Liner, Clonidine, Pharmaceutics

OC13323673 Page
25 Apr 2020
0
Pharmaceutics of patch dosage form (part 2) Major components: protective or release liner (peel strip, adhesive layer, rate controlling drug release me
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 14: Ischemia, Mydriasis, Pain Management

OC13323674 Page
25 Apr 2020
0
Pain : an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Pain is t
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 15: Stratum Corneum, Percutaneous, Partition Coefficient

OC13323673 Page
25 Apr 2020
0
Pharmaceutics of patch dosage form (part 1) Promote drug migration through the skin to the underlying blood supply without buildup in the skin. Stratum
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 13: Postherpetic Neuralgia, Ketoprofen, Diclofenac

OC13323673 Page
25 Apr 2020
0
Author"s conclusions: in chronic musculoskeletal conditions with assessments over 6 to 12 weeks, topical diclofenac and ketoprofen had limited efficacy
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 13: Orthostatic Hypotension, Chronic Pain, Nortriptyline

OC13323672 Page
25 Apr 2020
0
10 mg qhs, increase by no more than 10 mg weekly. Maximum dose : 150 mg (often limited by tolerability) Recommended initial : 10-25 mg qhs, increase by
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 11: NEUR Pathophysiology of Pain (Part 2)

OC13323673 Page
25 Apr 2020
0
Pathophysiology of acute and chronic pain (part 2) Definition: pain due to peripheral and central mechanisms as a result of disease or injury to a peri
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture Notes - Lecture 12: Postherpetic Neuralgia, Orthostatic Hypotension, Tricyclic Antidepressant

OC13323674 Page
25 Apr 2020
0
Pharmacology review of pain medications (part 2) Drug of choice in patients with co-existing depression. Block cortical ach, alpha, ha receptors sedati
View Document
UBCPHRM 211Karen DahriFall

PHRM 211 Lecture 10: NEUR Insomnia Therapeutics (Part 5)

OC13323673 Page
25 Apr 2020
0
All are considered off-label use for insomnia, except doxepin (approved by health canada for sleep maintenance, but rarely used). Dosage : 25-50 mg po
View Document